Comparing the detection of monoclonal
protein by means of presently available biochemocal methods
Špička I.1, Mecl J.2, Benáková H.3, Nohejlová A.1, Straub J.1, Novotová E.1, Zima T.3
1Klinika hematologie, I. interní klinika 1. LK UK a VFN Praha 2Oddělení biochemedicinského inženýrství, Nemocnice Na Homolce, Praha 3Ústav klinické biochemie a laboratorní diagnostiky 1. LF a VFN Praha
Clonal mature B-lymphocytes and plasma cells make monoclonal antibodies that can be detected by serum protein
electrophoresis (SPE) and immunofixation electrophoresis (IFE). These methods are used to diagnose myeloma and
other monoclonal gammapathies, and to monitor treatment and disease progression. They are surrogate markers that
allowed us to reduce the number of bone marrow biopsies and imaging scans that a patient would have to be subjected
to. The detection is more complicated in 10–20% of myeloma patients with light chain myeloma and was impossible in
2–3% patients with „non-secretory“ myeloma. New method is a detection of free light chain (FLC) in serum. In our study
we compare those three methods (SPE, IFE and FLC) from the viewpoint of sensitivity of paraprotein detection. For FLC
detection was used Freelite system analyzer (Immunotech Beckman Coulter). We examined 51 patients with diagnosis
of multiple myeloma, non-Hodgkin lymphoma, primary amyloidosis and monoclonal gammopathy of undetermined
significance. Detection of FLC is a valuable method which could sometimes specify diagnosis of MG and make
treatment more accurate.
multiple myeloma, detection of paraprotein, free light chains (FLC).